ClinicalTrials.gg
RecruitingNCT07377682Updated Nov 12, 2026

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

An observational study in Depression - Major Depressive Disorder and Cognition Disorders in Old Age, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Recruiting at 1 site in Poland. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 94 studies in Depression with a site in Poland — 18 open to participants now, 22 under way, 7 of them phase 3. Depression · Poland.

Planned enrollment
11th of 14
120 · median 391
Started
2025
with 15 others
Observational
14 of 94
4 open now
Primary completion
2026-12
later than 6 of 21 live
Registered
88th of 94
by date

Among the 94 studies in Depression with a site in Poland, this one is the 11th largest by planned enrollment of the 14 observational ones that give a count, is one of 16 that started in 2025, is one of 14 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 88th registered.

Depression

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

18 of the 94 studies in Depression with a site in Poland are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Depression with a site in Poland, or all of them as a file.
02

Study summary

TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data from standard clinical practice in Italy, Poland, and Romania

03

Conditions studied

  • Depression - Major Depressive Disorder
  • Cognition Disorders in Old Age

Keywords

  • Depression
  • Major Depressive Disorder
  • Cognition
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Major Depressive Disorder and mild cognition impairment treated with trazodone

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 55 or older.
  • Patients who meet the (DSM)-5 criteria for MDD diagnosis.
  • Patients experiencing a current major depressive episode of at least moderate severity, defined by a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20 at enrolment.
  • Patients with a diagnosis of MCI (also referred to as "mild neurocognitive disorder") according to the DSM-5 criteria.
  • Patients who start treatment with trazodone hydrochloride (prolonged release) with starting dosage according to SmPC at enrolment visit (or at latest within one week).
  • Patients legally capable of giving their written consent to participate in the study (including personal data processing) and willing to comply with all study procedures as per clinical judgement.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the to the administration of trazodone according to the approved local SmPC.
  • Known or allergy to the active ingredient and/or to any component of the study medication.
  • Concomitant treatment with other antidepressant drugs, mood stabilizers, antipsychotics, and/or proved resistance to trazodone monotherapy.
  • Patients with current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition.
  • Patients with previous or current history of any neurological condition that, in the opinion of the Investigator, might compromise participation in the study.
  • Patients participating in any interventional study in the 30 days prior to the enrolment visit.
  • Patients with ongoing pregnancy or breast-feeding at enrolment visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Depressive symptoms severity (MADRS)

    To describe the response in terms of depressive symptoms severity (as measured by Montgomery-Åsberg Depression Rating Scale \[MADRS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a widely used clinician-rated scale designed to measure the overall severity of core symptoms of depression in patients with MDD. It consists of 10 items: nine of the items are based upon patient report and one is on the rater's observation during the rating interview. MADRS items are rated on a 7-point scale, where 0 refers to the lack of the symptom and 6 refers to the most severe level of the symptom. The total score is the sum of the items and ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. The MADRS is completed by the Investigator at each scheduled visit and the results will be entered into the eCRF.

    Time frame: At 24 weeks from treatment

Secondary outcomes

  1. Depressive symptoms severity (MADRS)

    To describe the response in terms of depressive symptoms severity (as measured by MADRS) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a widely used clinician-rated scale designed to measure the overall severity of core symptoms of depression in patients with MDD. It consists of 10 items: nine of the items are based upon patient report and one is on the rater's observation during the rating interview. MADRS items are rated on a 7-point scale, where 0 refers to the lack of the symptom and 6 refers to the most severe level of the symptom. The total score is the sum of the items and ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. The MADRS will be completed by the Investigator at each scheduled visit and the results will be entered into the eCRF.

    Time frame: At 12 weeks from treatment

  2. Clinical response (CGI)

    To describe the clinical response (as measured by Clinical Global Impression \[CGI\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Clinical Global Impression (CGI) is a 3-item clinician-rated scale that measures the severity of psychopathology (CGI-S), the global improvement of the patient (CGI-I) and therapeutic response (CGI-E). CGI-S and CGI-I are rated on a 7-point scale. For CGI-S, a score of 1 indicates lack of illness and 7 indicates the greatest severity. For CGI-I, the score ranges from 1, referring to the biggest improvement, to 7, referring to the biggest worsening. CGI-E evaluates 2 dimensions of the therapeutic response, namely, the therapeutic effect and side effects, rated on 4 levels. The assessment is performed on a 4x4 scale, with scores ranging from 1 to 16. The CGI will be completed by the Investigator at V1 (only CGI-S) and V3 (or early termination visit) and the results will be entered into the eCRF

    Time frame: At 24 weeks from treatment

  3. Cognitive functioning (MoCA)

    To describe the response in terms of cognitive functioning (as measured by Montreal Cognitive Assessment \[MoCA\] and Repeatable Battery for the Assessment of Neuropsychological Status \[RBANS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Montreal Cognitive Assessment (MoCA) is a brief screening tool which includes 11 tasks assessing several cognitive domains, namely, memory, visuospatial abilities, executive functions, attention, concentration, language, and orientation to time and place. The total score ranges from 0 to 30. A score of 26 or above is considered normal, while scores below 26 indicate potential mild cognitive impairment or more serious. In addition, a correction for education is applied by adding 1 point for subjects with less than 12 years of education. The MoCA will be administered to the patient by the Investigator at V1 and V3 (or early termination visit) and the results will be entered into the eCRF.

    Time frame: At 24 weeks from treatment

  4. Sleep quality (SQS)

    To describe the response in terms of sleep quality (as measured by the single-item Sleep Quality Scale \[SQS\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The Sleep Quality Scale (SQS) is a single-item validated questionnaire evaluating overall quality of sleep using a visual analogue scale (VAS), with values ranging from 0 (terrible) to 10 (excellent). The recall period for the scale is seven days. The SQS is completed by the patient at V1 and V3 (or early termination visit) and the results will be and entered into the eCRF by the Investigator.

    Time frame: At 24 weeks from treatment

  5. To describe the response in terms of quality of life (EQ-5D-5L)

    To describe the response in terms of quality of life (as measured by the Euro-Quality of Life 5 dimensions - 5 level \[EQ-5D-5L\]) start among patients with moderate-severe MDD and with MCI treated with prolonged release trazodone. The EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L) is a brief and generic tool to measure patient-reported health status. It consists of two parts. EQ-5D-5L includes 5 questions covering 5 domains of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression). Each question is rated on 5 levels of response, ranging from no problems to extreme problems. The measure also includes a visual analogue scale (EQ-VAS) which requires patients to rate their own health from 0 to 100,representing, respectively, the worst and best imaginable health status. The EQ-5D-5L will be completed by the patient at V1 and V3 (or early termination visit) and the results will be entered into the eCRF by the Investigator.

    Time frame: At 24 weeks from treatment

  6. Absolute and relative frequency of patients

    Analyze the response absolute and relative frequency of patients with moderate-severe MDD and with MCI discontinuing trazodone during the study period and reasons for discontinuation. Analyze the response absolute and relative frequency of patients with moderate-severe MDD and with MCI starting another anti-depressant during the study period and type of anti-depressant. Analyze the response absolute and relative frequency of concomitant medications.

    Time frame: Over 24 weeks

  7. Serious adverse events of prolonged release trazodone

    Analyze the absolute and relative frequency of patients experiencing serious adverse events. Descriptive statistics will be provided for details of AEs, such as severity, outcome, seriousness, causality, and action taken. AEs will be coded using the MedDRA.

    Time frame: Over 24 weeks

  8. Drug related adverse events of prolonged release trazodone

    Analyze absolute and relative frequency of patients experiencing drug related adverse events. Descriptive statistics will be provided for details of AEs, such as severity, outcome, seriousness, causality, and action taken. AEs will be coded using the MedDRA.

    Time frame: Over 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Poradnia Medycyna Miłorząb: pl. Pokoju 3/4, 90-227 Łódź. Poland
    Lodz, Poland 93-005, Poland
    Recruiting
    • Marcin Stanisław Wojtera, MD, PhD, Psychiatrist · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 33 industry-sponsored observational studies under Depression, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 495 studies reached it within 32 months; a quarter within 13 and three quarters within 62.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Dec 2026 and completion Jul 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 30, 2026
StartActual
Dec 15, 2025
Primary completionEst.
Dec 2026was Jul 2026
CompletionEst.
Dec 2026was Jul 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Dec 2026
Nov 12, 2026
Study completion
Jul 2026→Dec 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jul 2026→Dec 2026
    Study completion Jul 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07377682
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Dec 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Alessandro Ruggieri
Contact
alessandro.ruggieri@angelinipharma.com
+393475665012
Raffaele Antonelli Incalzi
principal investigator · CAMPUS BioMedico

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion